Navigation Links
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Date:11/26/2007

hypertensives, and older and younger participants. Participants with Greater Than or Equal To 2 risk factors had risk reductions (RR) in both acute major coronary events (RR 43%) and coronary revascularization procedures (RR 37%). Because there were too few events among those participants with age as their only risk factor in this study, the effect of MEVACOR on outcomes could not be adequately assessed in this subgroup.

Figure 1

(Photo: http://www.newscom.com/cgi-bin/prnh/20071126/NEM105 )

Atherosclerosis

In the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT), the effect of therapy with lovastatin on coronary atherosclerosis was assessed by coronary angiography in hyperlipidemic patients. In the randomized, double- blind, controlled clinical trial, patients were treated with conventional measures (usually diet and 325 mg of aspirin every other day) and either lovastatin 20-80 mg daily or placebo. Angiograms were evaluated at baseline and at two years by computerized quantitative coronary angiography (QCA). Lovastatin significantly slowed the progression of lesions as measured by the mean change per-patient in minimum lumen diameter (the primary endpoint) and percent diameter stenosis, and decreased the proportions of patients categorized with disease progression (33% vs. 50%) and with new lesions (16% vs. 32%).

In a similarly designed trial, the Monitored Atherosclerosis Regression Study (MARS), patients were treated with diet and either lovastatin 80 mg daily or placebo. No statistically significant difference between lovastatin and placebo was seen for the primary endpoint (mean change per patient in percent diameter stenosis of all lesions), or for most secondary QCA endpoints. Visual assessment by angiographers who formed a consensus opinion of overall angiographic change (Global Change Score) was also a secondary endpoint. By t
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN THE ... The National Institutes of Health is convening a Pathways ... on the long-term effectiveness and potential risks of opioids ... nation,s top experts in the field of pain control ... key NIH scientists who focus on pain related research. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all about ... can be treated. , A medically retired Army veteran, ... platoon sustained multiple attacks resulting in five casualties. After ... PTSD and honorably discharged from the Army. , “I ... myself from my friends and family,” recalled O’Farrell, who ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dr. Connie Casad ... medical practices to new office space at 12200 Park Central ... at the office will be Park Cities Aesthetics, Optimal Health ... , In announcing her move, Dr. Casad said, “The patients’ ... treatment they select, we want them to always feel like ...
(Date:9/23/2014)... used to diagnose lung cancer may not be as reliable ... a new analysis says. One noninvasive way of ... as functional imaging. For lung cancer, a specific type of ... authors. Cancerous tumors generally look different on FDG-PET images ... have cancer, according to background information in the study. But, ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Avid collector Andrew ... 1967 The Doors Eagle Auditorium Seattle concert posters. The Doors ... “Break On Through” that year. The Seattle Eagles Auditorium concert ... “The Doors would return to Eagles Auditorium in November the ... is not known and comes in three colors. The poster ...
Breaking Medicine News(10 mins):Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Dr. Connie Casad Moving to New Office Location 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2
... in the spread of lung cancer as well as a likely ... study was published today (Monday, March 14) in the Journal ... The University of Texas MD Anderson Cancer Center found a way ... that shifts primary tumor cells into a more deadly type of ...
... Harbor, N.Y In a research study appearing in the ... Cold Spring Harbor Laboratory (CSHL) and four other institutions have ... which currently has limited treatment options and one of the ... experiments reveal that up to 15% of liver tumors are ...
... March 14, 2011The first human studies of an oral drug ... promising near 50% reduction in HIV incidence, but a number ... can be implemented on a large scale, according to an ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( www.liebertpub.com ...
... Reporter , MONDAY, March 14 (HealthDay News) -- An ... earthquake-ravaged Japan,s Fukushima Dai-ichi nuclear complex, but officials insisted ... to news reports. Authorities had been scrambling ... earthquake and tsunami knocked out water systems and backup ...
... major study of the wellbeing and inclusion of former ... by Queen,s University today (Monday 14 March). ... in Northern Ireland and the border region of Ireland ... of loyalist and republican former prisoners (aged 50 and ...
... Researchers at Georgia Health Sciences University are studying ... protective metabolite could halt the progression of diabetic nephropathy, ... four year, $308,000 grant from the American Heart Association, ... the College of Dental Medicine and Pharmacology and Toxicology ...
Cached Medicine News:Health News:Study puts notch on the jagged edge of lung cancer metastasis 2Health News:Study puts notch on the jagged edge of lung cancer metastasis 3Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 2Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 3Health News:Early success of anti-HIV preventive oral drug regimen is promising, but questions remain 2Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 2Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 3Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 4Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3
(Date:9/23/2014)... Sept. 23, 2014 The Pennsylvania State Police will ... 27, as part of National Prescription Drug Take-Back Day. ... Take-Back Day is a national initiative, conducted ... aimed at encouraging the public to dispose of expired, ... abuse and theft. From 10 a.m. to ...
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
(Date:9/23/2014)... Iowa , Sept. 23, 2014  KemPharm, ... the discovery and development of proprietary new molecular ... a No Objection Letter (NOL) from Health Canada ... for its lead product candidate KP201 ... prodrug in development for acute moderate to moderately ...
Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... Calif., Aug. 2, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the following investor ... Conference Location: Intercontinental Hotel, Boston, MA Presentation ... Wedbush Life Sciences ...
... Mich., Aug. 2, 2011 Perrigo Company (Nasdaq: PRGO;TASE) today ... quarter fiscal 2011 on Tuesday, August 16 , 2011 at ... call at 10:00 a.m. (ET) hosted by Joseph C. Papa, ... call will be available live via webcast to interested parties ...
Cached Medicine Technology:
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: